PHARMA & FLO
The computed 12-month bankruptcy probability of PHARMA & FLO is 0.5% (low). The 2024 annual accounts show equity of €1.45M and a net result of €315k. Equity is growing by ~17.3% per year across the filed fiscal years. Its solvency ranks better than 84% of 858 sector peers (fiscal year 2024). The company has been active since 1996 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €1.45M |
| Net result | €315k |
| Staff (FTE) | 8.1 |
| Better than sector | 84% |
Exceptional profile, strong across almost every axis.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Unlock the full score breakdown, per-year score history and the indicative credit limit with Plus.
See plans →How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 55.7% | 17.5% | |
| Net result | €315k | €14k | |
| Equity | €1.45M | €101k | |
| Gross operating margin | €762k | €213k | |
| Staff costs | €445k | €219k |
| Fiscal year | 2024 |
|---|---|
| Revenue | - |
| EBITDA | €310k |
| Net profit | €315k |
| Cash flow | €321k |
| Staff costs | €445k |
| Income taxes | €104k |
| Dividends | €285k |
| Total assets | €2.60M |
| Equity | €1.45M |
| Debt | €1.15M |
| of which ≤ 1y | €1.02M |
| of which > 1y | €133k |
| Working capital | €526k |
| Employees (FTE) | 8.1 |
| 2024 | |
|---|---|
| Current ratio | 1.51 |
| Quick ratio | 1.14 |
| Working capital ratio | 20.2% |
| Solvency | 55.7% |
| Debt / equity | 0.80 |
| Long-term debt ratio | 0.09 |
| Interest coverage | 51.58 |
| Gross margin | - |
| Net margin | - |
| ROA | 12.1% |
| ROE | 21.7% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
| Line item | Code | 2024 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €2.60M |
| Fixed assets | 21/28 | €1.06M |
| Tangible fixed assets | 22/27 | €16k |
| Financial fixed assets | 28 | €1.04M |
| Current assets | 29/58 | €1.55M |
| Stocks & contracts in progress | 3 | €384k |
| Amounts receivable within one year | 40/41 | €730k |
| Cash & bank | 54/58 | €424k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €2.60M |
| Equity | 10/15 | €1.45M |
| Contributions / capital | 10/11 | €19k |
| Reserves | 13 | €1.37M |
| Accumulated profits (losses) | 14 | €62k |
| Amounts payable | 17/49 | €1.15M |
| Amounts payable after one year | 17 | €133k |
| Amounts payable within one year | 42/48 | €1.02M |
| Trade debts payable within one year | 44 | €207k |
| Income statement | ||
| Gross operating margin | 9900 | €762k |
| Operating result | 9901 | €305k |
| Financial income | 75 | €121k |
| Financial charges | 65 | €6k |
| Result before taxes | 9903 | €419k |
| Income taxes | 67/77 | €104k |
| Net result for the period | 9904 | €315k |
| Result to be appropriated | 9905 | €315k |
| NACE primary | Retail trade(47730) |
| Legal form | Private limited company(610) |
| Incorporation | 29-06-1996 |
| Status | Active |
| Postal code | 5100 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 92067B0374/00A000 | Wallonia | 471 m² | 1 · 425 m² | 24.3 m · 7 fl. |
| 92322F0766/00_000 | Wallonia | 210 m² | 1 · 95 m² | 14.4 m · 4 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
26-02-2025 Change in the board of directors
Technical details
{
"events": [
{
"kind": "substantive_delegation",
"role": "bestuurder",
"person": {
"rrn": "*25314510*",
"name": "Thierry DELAHAUT",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": "confirmation",
"via_org": null,
"statutory": "statutair",
"compensated": null,
"effective_date": null,
"evidence_quote": "",
"decharge_status": null,
"mandate_duration": {
"kind": "indefinite",
"value": null
},
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
},
{
"kind": "substantive_delegation",
"role": "bestuurder",
"person": {
"rrn": "*25314510*",
"name": "Thierry DELAHAUT",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": "confirmation",
"via_org": null,
"statutory": "statutair",
"compensated": null,
"effective_date": null,
"evidence_quote": "",
"decharge_status": null,
"mandate_duration": {
"kind": "indefinite",
"value": null
},
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
}
],
"notary": {
"name": "Louis JADOUL",
"firm_city": null,
"firm_name": null,
"office_city": "Namur",
"is_associated": false
},
"act_meta": {
"language": "mixed",
"pub_date": "2025-02-26",
"filing_date": "2025-02-24",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decisions": [
{
"body": "buitengewone_algemene_vergadering",
"date": "2025-02-25",
"unanimous": true
}
],
"is_correction": false,
"subject_company": {
"kbo": "0458.489.207",
"name_full": "PHARMA \u0026 FLO",
"legal_form": "SRL"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Louis JADOUL",
"org_rep_person_name": null,
"person_role_at_subject": "notaire"
},
"co_filed_documents": [],
"corrected_publication_numac": null
}Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameFR | PHARMA & FLO |